Condition: Chronic Cluster Headache · Sponsor: Salvia BioElectronics
This is a limited open-label study being performed at two centers in the Netherlands. All participants will receive the same treatment, and both the patients and doctors will know what that treatment is. The goal is to see how safe and effective the PRIMUS system is for preventing Chronic Cluster Headaches (CCH) in people who haven't responded well to the drug verapamil. The study will also look at the patients' experience using the system.
This description comes directly from the study's public registry record.
Rolf Fronczek, Dr. · +31715262197 · hoofdpijnonderzoek@lumc.nl
Always discuss trial participation with your own doctor first.
| LUMC Leids Universitair Medisch Centrum | Leiden, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07113470